{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"4"}],"title":"Alive"},{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"}],"title":"Dead"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"groups":[{"description":"This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).","id":"OG000","title":"Dose Level 1: Clofarabine at 20 mg/m^2/Dose x 5 + THIO-MEL"},{"description":"This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).","id":"OG001","title":"Dose Level 2: Clofarabine at 30 mg/m^2/Dose x 5 + THIO-MEL"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Participants"}